Drugs / ELENAGEN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05979298 | Nov 2019 → Dec 2024 | ovarian cancer | CureLab Oncology | Unknown | Met primary |
News releases announcing trial results or a regulatory action · 45
| Date | Issuer | Release |
|---|---|---|
| 2026-09-03 | CureLab Oncology | Results Landmark Phase II study in platinum-resistant ovarian cancer to be presented at ESGO 2026 curelaboncology.com ↗
The oral presentation, titled Randomized Phase II Study of P62/Sqstm1-Encoding Plasmid (Elenagen) In Combination With Gemcitabine for Platinum-Resistant Ovarian Cancer ( Abstract 274) , details results from a randomized Phase II clinical trial evaluating the DNA-based therapy Elenagen (p62/SQSTM1-encoding plasmid) in combination with gemcitabine. |
| 2026-09-03 | CureLab Oncology | Regulatory Hormone-resistant prostate and breast cancers added to clinical study based on encouraging preliminary results curelaboncology.com ↗
The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology ’s Elenagen ™, an experimental DNA therapy, to include two new arms: 1) hormone-resistant breast cancer; and 2) hormone-resistant metastatic prostate cancer. |
| 2026-09-03 | CureLab Oncology | Results Elenagen, a novel DNA immunotherapy for the deadliest form of ovarian cancer, delays disease progression curelaboncology.com ↗ |
| 2026-09-03 | CureLab Oncology | Results A Newly Published Paper Demonstrates That A Novel DNA-Based Therapy Called Elenagen Achieves Significant Reduction in Mortality and an Increase In Overall Survival in Platinum Resistant Ovarian Cancer curelaboncology.com ↗
In the reporting, researchers supplementing the standard of care (chemotherapy) with Elenagen, have significantly extended overall survival for patients with the deadliest form of ovarian cancer. |
| 2026-04-13 | CureLab Oncology | Results A Novel Approach to Platinum-Resistant Ovarian Cancer: Results from the Elenagen Phase II Study (ESGO 2026) curelaboncology.com ↗
The oral presentation, titled Randomized Phase II Study of P62/Sqstm1-Encoding Plasmid (Elenagen) In Combination With Gemcitabine for Platinum-Resistant Ovarian Cancer (Abstract 274), detailed results from a randomized Phase II clinical trial e valuating the DNA-based therapy Elenagen (p62/SQSTM1-encoding plasmid) in combination with gemcitabine. |
| 2026-02-26 | CureLab Oncology | Results Elenagen Phase II Data in Platinum-Resistant OC curelaboncology.com ↗
The randomized study, recently published in the International Journal of Gynecological Cancer, reported a doubling of median overall survival, from approximately 13 months with chemotherapy alone to more than 25 months with the addition of Elenagen. |
| 2026-02-25 | CureLab Oncology | Results Alexander Shneider: Elenagen Combination Extends Survival in Ovarian Cancer curelaboncology.com ↗
Doubling of Median Survival: 13 → 25+ months in this study |
| 2026-02-19 | CureLab Oncology | Results Elenagen helps women with ovarian cancer live 1 year longer curelaboncology.com ↗
With Elenagen, overall survival averaged 25 months, or slightly longer than two years, compared with 13 months without. |
| 2026-02-16 | CureLab Oncology | Results Survival Rates Near Double With Experimental Therapy In Ovarian Cancer curelaboncology.com ↗
Patients treated with the combination lived significantly longer overall than those on chemotherapy alone, with median survival in the elenagen group surpassing 25 months, compared with about 13 months for the control group receiving only gemcitabine. |
| 2026-02-16 | CureLab Oncology | Results DNA Therapy Doubles Ovarian Cancer Survival curelaboncology.com ↗
Researchers found that the combination therapy reduced mortality risk up to 59% and significantly outperformed chemotherapy alone, particularly in high-risk patients with elevated CA-125 levels. |
| 2026-02-15 | CureLab Oncology | Results Experimental drug doubles survival of ovarian cancer patients in trial curelaboncology.com ↗
Patients in the elenagen group lived significantly longer, with a median survival of more than 25 months, compared to roughly 13 months with gemcitabine alone. |
| 2026-02-14 | CureLab Oncology | Results Health Rounds: Experimental drug doubles survival of ovarian cancer patients in trial curelaboncology.com ↗
Patients in the elenagen group lived significantly longer, with a median survival of more than 25 months, compared to roughly 13 months with gemcitabine alone. |
| 2026-02-13 | CureLab Oncology | Results Un fármaco experimental duplica la supervivencia en cáncer de ovario resistente curelaboncology.com ↗
Los resultados fueron contundentes: las pacientes que recibieron elenagen presentaron una mediana de supervivencia superior a 25 meses , frente a aproximadamente 13 meses con gemcitabina sola, lo que se traduce en casi el doble de tiempo de vida. |
| 2026-02-13 | CureLab Oncology | Results Rondes de santé : Un médicament expérimental double la survie des patientes atteintes d’un cancer de l’ovaire curelaboncology.com ↗
Les patientes du groupe elenagen ont vécu beaucoup plus longtemps, avec une survie médiane de plus de 25 mois, contre environ 13 mois avec la gemcitabine seule. |
| 2026-02-13 | CureLab Oncology | Results Health Rounds: Experimental drug doubles survival of ovarian cancer patients in trial curelaboncology.com ↗
Patients in the elenagen group lived significantly longer, with a median survival of more than 25 months, compared to roughly 13 months with gemcitabine alone. |
| 2026-02-13 | CureLab Oncology | Results Experimental Drug Doubles Ovarian Cancer Survival curelaboncology.com ↗
Patients in the elenagen group lived significantly longer, with a median survival of more than 25 months, compared to roughly 13 months with gemcitabine alone. |
| 2026-02-13 | CureLab Oncology | Results Cancer de l’ovaire avancé : ce traitement expérimental a presque doublé la survie de patientes qu’on pensait condamnées curelaboncology.com ↗
Dans cette population à très mauvais pronostic, l'ajout du médicament Elenagen à une chimiothérapie classique a presque doublé la durée de survie médiane, selon les premières données publiées. |
| 2026-02-11 | CureLab Oncology | Results Overall survival benefit with elenagen plus gemcitabine in platinum-resistant ovarian cancer curelaboncology.com ↗
Patients receiving elenagen plus chemotherapy lived significantly longer than those receiving chemotherapy alone. |
| 2026-01-29 | CureLab Oncology | Results Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer curelaboncology.com ↗
The addition of elenagen, a plasmid DNA-based immunomodulatory agent encoding the p62/SQSTM1 protein, to gemcitabine therapy significantly improved overall survival compared with gemcitabine monotherapy for patients with platinum-resistant ovarian cancer, according to phase 2 study results published in the International Journal of Gynecological Cancer. |
| 2026-01-23 | CureLab Oncology | Results HMN 2026: How A novel DNA-based therapy achieves significant increase in overall survival in platinum resistant ovarian cancer curelaboncology.com ↗
In the reporting, researchers supplementing the standard of care (chemotherapy) with Elenagen, have significantly extended overall survival for patients with the deadliest form of ovarian cancer. |
| 2026-01-15 | CureLab Oncology | Results Therapy could increase ovarian cancer survival, paper finds – Drug Discovery World (DDW) curelaboncology.com ↗
A new clinical study, published in the International Journal of Gynecological Cancer , shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival rates for patients with the deadliest form of ovarian cancer. |
| 2026-01-15 | CureLab Oncology | Results Novel DNA-based therapy achieves reduction in mortality in resistant ovarian cancer curelaboncology.com ↗
The research shows that the agent, when combined with chemotherapy, increased overall survival compared with chemotherapy alone. |
| 2026-01-13 | CureLab Oncology | Results Novel DNA-Based Therapy Called Elenagen, from CureLab Oncology, Achieves Significant Reduction in Mortality and an Increase in Overall Survival in Platinum‑Resistant Ovarian Cancer – BioQuick News curelaboncology.com ↗
Elenagen plus chemotherapy lived significantly longer than those who received chemotherapy alone |
| 2026-01-13 | CureLab Oncology | Results A novel DNA-based therapy achieves significant increase in overall survival in platinum resistant ovarian cancer curelaboncology.com ↗
In the reporting, researchers supplementing the standard of care (chemotherapy) with Elenagen, have significantly extended overall survival for patients with the deadliest form of ovarian cancer. |
| 2026-01-12 | CureLab Oncology | Results Uma Nova Terapia Baseada Em DNA Alcança Aumento Significativo Na Sobrevida Global No Câncer De Ovário Resistente à Platina curelaboncology.com ↗
Um novo estudo clínico publicado no International Journal of Gynecological Cancer relata resultados encorajadores para mulheres que enfrentam câncer de ovário resistente à platina (PROC). |
| 2026-01-12 | CureLab Oncology | Results Novel DNA Therapy Elenagen Shows Promise for Platinum-Resistant Ovarian Cancer curelaboncology.com ↗
Elenagen DNA therapy with gemcitabine benefits women with PROC and high CA-125 levels. |
| 2026-01-12 | CureLab Oncology | Results A novel DNA-based therapy achieves significant increase in overall survival in platinum resistant ovarian cancer curelaboncology.com ↗
In the report, researchers supplementing the standard of care (chemotherapy) with Elenagen significantly extended overall survival for patients with the deadliest form of ovarian cancer. |
| 2025-07-31 | CureLab Oncology | Results Investigational Anti-Cancer DNA Therapy Eases Chronic Osteoarthritis Pain in Dogs—Pointing to a New Non-Opioid Path for Humans curelaboncology.com ↗
The results were impressive: 90% of the dogs experienced at least a 1‑point decrease in Pain Severity Score and a 2‑point drop in Pain Interference Score, with median scores falling dramatically—from 5.25 to 3.25 and from 7.00 to 3.27, respectively—by day 70. |
| 2025-07-25 | CureLab Oncology | Results Could a Stem Cell Arthritis Treatment for Dogs Work in Humans? Pain News Network Explores Elenagen’s Promise curelaboncology.com ↗ |
| 2025-07-24 | CureLab Oncology | Results Investigational anti-cancer DNA therapy eases chronic osteoarthritis pain in dogs—pointing to a new non-opioid path for humans curelaboncology.com ↗
Elenagen reduced osteoarthritis pain scores in companion dogs. |
| 2024-11-14 | CureLab Oncology | Regulatory CureLab Oncology Seeks to Revolutionize Chronic Pain Management with Novel p62-Based Therapy curelaboncology.com ↗
CureLab Oncology a clinical-stage biotech company dedicated to pioneering innovative therapies, announced a patent application for an innovative chronic pain treatment centered on its p62/SQSTM1 DNA plasmid. |
| 2024-08-15 | CureLab Oncology | Results CureLab Oncology’s Elenagen: DNA Vaccine Shows Promise in Immuno-Oncology and Beyond curelaboncology.com ↗
In a Phase 2 clinical trial for platinum-resistant ovarian cancer, Elenagen combined with gemcitabine chemotherapy significantly improved progression-free survival compared to gemcitabine alone (7.2 months vs. 2.7 months) |
| 2024-06-20 | CureLab Oncology | Results Breakthroughs and challenges in therapeutic cancer vaccines: A new era of hope? curelaboncology.com ↗
The 2024 study found the treatment increased progression free survival from 2.8 months to 7.2 months compared to chemotherapy. |
| 2024-06-14 | CureLab Oncology | Results Healing by Proxy: Newly Discovered Drug Elenagen May Treat Cancer and Inflammation Through Indirect Action curelaboncology.com ↗ |
| 2024-03-20 | CureLab Oncology | Results Elenagen, a novel DNA immunotherapy for the deadliest form of ovarian cancer, delays disease progression curelaboncology.com ↗
CureLab Oncology , a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been shown to significantly enhance standard chemotherapy and provides clinical benefits for the patients with the deadliest form ovarian cancer. |
| 2024-02-29 | CureLab Oncology | Results Study undermines mechanism-based discovery, says CureLab curelaboncology.com ↗
CureLab Oncology’s DNA vaccine Elenagen, in combination with chemotherapy, has demonstrated promising clinical results against triple-negative ovarian cancer. |
| 2024-02-22 | CureLab Oncology | Results Elenagen, a novel DNA immunotherapy for ovarian cancer, found to delay disease progression curelaboncology.com ↗
The study, published in Frontiers in Oncology, shows that disease progression was significantly delayed in a group of stage III and IV platinum-resistant ovarian cancer (PROC) patients who received gemcitabine in combination with Elenagen, compared to the group who received gemcitabine alone. |
| 2023-12-04 | CureLab Oncology | Results DNA therapy effective against chemo-resistant ovarian cancer curelaboncology.com ↗
In a new paper, a team of scientists from CureLab Oncology, the NN Alexandrov National Cancer Center and Minsk City Oncology Center have demonstrated a clear clinical benefit of the new biological agent against advanced platinum-resistant ovarian cancer. |
| 2023-09-29 | CureLab Oncology | Results Novel DNA vaccine Elenagen demonstrates promising clinical results curelaboncology.com ↗
In a preprint paper published on MedRxiv, a team of scientists at CureLab Oncology and their international collaborators have demonstrated a clear clinical benefit of a new biological agent against the deadliest form of ovarian cancer. |
| 2023-07-16 | CureLab Oncology | Regulatory CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in India curelaboncology.com ↗ |
| 2022-09-10 | CureLab Oncology | Results ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival curelaboncology.com ↗
A statistically significant prolongation of PFS was clearly demonstrated in the trial and continues to extend as the trial continues. |
| 2021-11-11 | CureLab Oncology | Results OncologyTube interviews Dr. Alex Shneider of CureLab Oncology and Prof. Sergei Krasny curelaboncology.com ↗
when Elenagen was added to the treatment regimen, all patients showed complete or partial regression of the primary tumor and associated metastases in the lungs, liver, lymph nodes, and bones. |
| 2021-09-16 | CureLab Oncology | Results CureLab Oncology Presents at 2021 ESMO Congress curelaboncology.com ↗
Experimental results indicate a mitigation of chronic inflammation and stimulation of an immune response to the tumor. |
| 2021-08-11 | CureLab Oncology | Regulatory Hormone-Resistant Prostate and Breast Cancers Added to Clinical Study Based on Encouraging Preliminary Results curelaboncology.com ↗
The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology’s Elenagen™ , an experimental DNA therapy, to include two new arms: 1) hormone-resistant breast cancer; and 2) hormone-resistant metastatic prostate cancer. |
| 2021-06-30 | CureLab Oncology | Regulatory CureLab Oncology Submits Patent for COVID Therapeutic Ahead of Phase I Clinical Trials curelaboncology.com ↗ |
All press releases naming this drug 48 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELENAGEN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05979298 ↗ |
| Modality | Other / unclassified | “novel anticancer therapeutic DNA plasmid” PMID 38410116 ↗ Feb 2024 |
| Route | Intramuscular | “ELENAGEN (2.5 mg i.m. weekly)” NCT05979298 ↗ |